miR-93-5p, an effector of the TGF-β signalling pathway in prostate cancer, has been predicted to act on and bind to BAMBI, consequently inhibiting BAMBI expression and activating TGF-β signalling [103]. This evidence concerns the gene TGFB1 and prostate carcinoma.